SCHEMBL960250

SCHEMBL960250

Oc1cccc(-c2nc(Cl)c3sccc3n2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.59
MTOR P42345 2/20 0.59
PIK3C2B O00750 1/20 0.58
CCNE2 O96020 1/20 0.58
PRKACA P17612 1/20 0.58
PRKACG P22612 1/20 0.58
PRKACB P22694 1/20 0.58
CCNE1 P24864 1/20 0.58
CDK2 P24941 1/20 0.58
KDR P35968 1/20 0.58
PIK3CB P42338 1/20 0.58
PIK3CG P48736 1/20 0.58
HSD17B2 P37059 7/20 0.46
HSD17B1 P14061 7/20 0.46
CYP19A1 P11511 1/20 0.43
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1094879 0.84 PIK3CA (0.58) PIK3CAMTORPIK3C2BCCNE2PRKACA
SCHEMBL14103869 0.82 RAB9A (0.47) PIK3CAMTORPIK3C2BCCNE2PRKACA
SCHEMBL14103880 0.82 DHPS (0.43) PIK3CAMTORPIK3C2BCCNE2PRKACA
SCHEMBL14103871 0.82 PIK3CA (0.42) PIK3CAMTORPIK3C2BCCNE2PRKACA
SCHEMBL4744102 0.81 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL1093085 0.80 PIK3CA (0.49) PIK3CAMTORPIK3C2BCCNE2PRKACA
SCHEMBL1093962 0.80 PIK3CA (0.57) PIK3CAMTORPIK3C2BCCNE2PRKACA
SCHEMBL1095288 0.80 PIK3CA (0.57) PIK3CAMTORPIK3C2BCCNE2PRKACA
SCHEMBL14104064 0.79 CYP1A2 (0.51) CYP19A1LMNATP53NFKB1RAB9A
SCHEMBL29395996 0.79 CYP1A2 (0.51) CYP19A1LMNATP53NFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812446-B1 PHARMACEUTICAL COMPOUNDS PIRAMED LTD (GB) 2015-11-18 EP disclosed
US-7872003-B2 Pharmaceutical compounds F. HOFFMANN-LA ROCHE AG (CH) 2011-01-18 US disclosed
US-20080207609-A1 Pharmaceutical compounds PLRAMED LIMITED (GB) 2008-08-28 US disclosed
EP-1812446-A1 PHARMACEUTICAL COMPOUNDS Piramed Limited (GB) 2007-08-01 EP disclosed
WO-2006046040-A1 PHARMACEUTICAL COMPOUNDS PIRAMED LIMITED (GB) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207609-A1 Pharmaceutical compounds PIK3CA, JAK2, PIK3R1 PIK3CA 1/4885MTOR 21/4885PIK3C2B 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.